Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF).
Tryp has concluded its Phase 1b study of TRP-8803, an IV-infused psilocin-based formulation, in obese participants.
Conducted at CMAX Clinical Research in Adelaide, the trial safely administered the treatment to three participants over a 140-minute period, completing the study within a week.
This rapid timeframe highlights the formulation’s scalability and potential.
TRP-8803 is designed to provide neuroplastic benefits, with applications for adaptive brain changes linked to psychiatric improvements.
The study generated valuable human data to optimise dosing for upcoming Phase 2 trials, targeting weight-related conditions such as Binge Eating Disorder.
Results, expected by the year’s end, will guide the advanced planning of the Phase 2 program. Tryptamine noted that all participants were safely discharged post-administration, marking a significant milestone in demonstrating the formulation’s potential to deliver improved health outcomes efficiently.
The company emphasises TRP-8803’s broad research opportunities and looks forward to leveraging the final dataset to explore its efficacy in addressing unmet medical needs within large market opportunities.